Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Conditions
PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · NSCLC · RAS Mutation · MTAP Deletion · Lung Cancer · Pancreatic Cancer Metastatic · Thoracic Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
Contact: Principal Investigator (Mitesh Borad, MD)Sarah Cannon Research Institute Denver, Denver, Colorado, United States
Contact: Principal Investigator (Gerald Falchook, MD, MS)Georgetown University Medical Center, Washington D.C., District of Columbia, United States
Contact: Principal Investigator (Marcus Noel, MD)Mayo Clinic Jacksonville, Jacksonville, Florida, United States
Contact: Principal Investigator (Hani Babiker, MD)Northwestern Memorial Hospital, Chicago, Illinois, United States
Contact: Principal Investigator (Chengwei Peng, MD)University of Indiana, Indianapolis, Indiana, United States
Contact: Principal Investigator (Anita Turk, MD)University of Iowa Health Care, Iowa City, Iowa, United States
Contact: Principal Investigator (Naomi Fei, MD, MS)Massachusetts General Hospital, Boston, Massachusetts, United States
Contact: Principal Investigator (Harshabad Singh, MD)Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Kimberly Perez, MD)Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Contact: Principal Investigator (Kaushal Parikh, MD)Nebraska Cancer Specialists, Omaha, Nebraska, United States
Contact: Principal Investigator (Joel Michalski, MD, PhD)NYU Langone Health, New York, New York, United States
Contact: Principal Investigator (Kristen Spencer, DO, MPH)Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Principal Investigator (Eileen O'Reilly, MD)University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Contact: Principal Investigator (Shetal Patel, MD, PhD)University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Jordi Rodon Ahnert, MD)NEXT Dallas, Irving, Texas, United States
Contact: Principal Investigator (Siraj Sen, MD)Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
Contact: Principal Investigator (Vaia Florou, MD, MS)NEXT Oncology, Fairfax, Virginia, United States
Contact: Principal Investigator (Alexander Spira, MD, PhD)
Study leads
Maxim Pimpkin, MD, PhD
Study Director
Tango Therapeutics, Inc.